What's breaking now, across thousands of outlets.
The FDA has granted accelerated approval to Johnson & Johnson’s cancer shot Rybrevant in head and neck cancer that’s come back after previous chemotherapy and immunotherapy. The approval is the first in a decade for ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into patient DNA — could raise new questions for the gene therapy field.
(MedPage Today) -- We've nominated medicine's biggest culture makers and moments of 2026. It's your turn to vote.
The results of a study found that women with higher blood levels of two common PFAS were more likely to develop estrogen receptor-negative breast cancer, saying their results have important public…
(MedPage Today) -- The following is a transcript of the podcast episode: Rachael Robertson: Hey everybody! Welcome to MedPod Today, the podcast series where MedPage Today reporters share deeper…
The Invesco Pharmaceuticals ETF continues to outperform as other areas of the market weaken, making it an investment opportunity worth watching.
An expert told Newsweek that carrying an inherited genetic change linked to cancer does not equal developing cancer.
